News Releases May 16, 2024 Ventyx Biosciences to Participate in Three Upcoming Investor Conferences Read more May 16, 2024 Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer Read more May 9, 2024 Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress Read more May 2, 2024 Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024 Read more March 11, 2024 Ventyx Biosciences Reports Clinical Data for its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor Event Read more March 7, 2024 Ventyx Biosciences Announces $100 Million Private Placement of Common Stock Read more March 6, 2024 Ventyx Biosciences to Participate in Two Upcoming Investor Conferences Read more March 4, 2024 Ventyx Biosciences to Host Virtual Investor Event on March 11, 2024 Read more February 27, 2024 Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress Read more February 22, 2024 Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the European Crohn's and Colitis Organisation (ECCO) Read more First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page › Last page » Displaying 11 - 20 of 66
